The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
BeiGene regains rights to tislelizumab as another oncology asset blows up for Novartis.
Momelotinib gains full US approval in a broader setting than expected, validating GSK’s $1.9bn buyout of Sierra Oncology.
Disclosure of BMS-986442’s second target antigen endorses Agenus, and is highly relevant for GSK and Compugen too.
The big pharma group had two anti-BCMA assets to choose from, and yesterday gave Harpoon the bad news.
Lung cancer will soon join melanoma as a phase 3 indication for mRNA-4157, an asset Merck & Co last year endorsed to the tune of $250m.
A flurry of activity around USP1 inhibition suggests growing interest in this novel DNA damage response mechanism.